IVIG Treatment and Prognosis in Guillain–Barré Syndrome by van Doorn, Pieter A. et al.
IVIG Treatment and Prognosis in Guillain–Barré Syndrome
Pieter A. van Doorn & Krista Kuitwaard &
Christa Walgaard & Rinske van Koningsveld &
Liselotte Ruts & Bart C. Jacobs
Published online: 16 April 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Introduction Guillain–Barré syndrome (GBS) is an acute,
immune-mediated polyneuropathy that often leads to severe
weakness. Intravenous immunoglobulin (IVIG) is a proven
effective treatment for GBS (class 1 evidence). However,
about 25% of patients need artificial ventilation and 20%
are still unable to walk unaided after 6 months. Important
clinical factors associated with poor outcome are age,
presence of preceding diarrhea and the severity of disability
in the early course of disease. These clinical factors were
combined in a clinical prognostic scoring scale, the
Erasmus GBS Outcome Scale (EGOS).
Materials and Methods GBS patients being unable to walk
unaided are currently treated with a standard single IVIg
dose (0.4 g/kg bodyweight for 5 days). A recent retrospec-
tive study in 174 GBS patients enrolled in one of our
randomized controlled clinical trials showed that patients
with a minor increase of serum IgG level after standard
single IVIg dose recovered significantly slower. Addition-
ally, fewer patients reached the ability to walk unaided at
six months after correction for the known clinical prognos-
tic factors (multivariate analysis; P<0.022).
Discussion It is yet unknown why some GBS patients only
have a minor increase after standard IVIg treatment. By
using the EGOS it is possible to select GBS patients with a
poor prognosis. These patients potentially may benefit from
a second IVIg dose.
Conclusion A standard dose of IVIG is not sufficiently
effective in many GBS patients. Whether these patients might
benefit from a second IVIg dose needs further investigation.
Keywords Guillain–Barré syndrome.IVIG.treatment.
prognosis
Introduction
Guillain–Barré syndrome (GBS) is a frequent cause of
neuromuscular paralysis occurring at all ages. The inci-
dence of GBS is reported to be 1.2–2.3 per 100,000 per
year [1, 2]. GBS is a postinfectious disorder. The most
frequently identified preceding infection is Campylobacter
jejuni. Others are cytomegalovirus, Epstein–Barr virus,
Mycoplasma pneumoniae, and Haemophilus influenzae [1,
3]. Many reports have documented the occurrence of GBS
shortly after vaccinations, operations, or stressful events,
but the causality and pathophysiology are still debated [2].
Main Features of GBS
The main features of GBS are rapid progressive bilateral and
relative symmetrical weakness of the limbs with or without
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muscles or sensory disturbances [4]. Patients have decreased
or absent tendon reflexes. Cerebrospinal fluid examination
typically shows an increased protein level with a normal
white cell count. Pain frequently occurs and may cause
severe complaints. It often starts before the onset of
weakness and therefore can lead to diagnostic difficulties.
Diagnostic criteria for GBS are shown in the Table 1.
Electromyography (EMG) can be helpful in confirming the
diagnosis in clinically difficult cases such as in patients with
extreme pain. EMG is especially useful for subclassifying
GBS into subgroups such as acute motor axonal neuropathy
(AMAN) and acute inflammatory demyelinating polyneur-
opathy (AIDP).
Clinical Course of GBS
Rapidly progressive weakness is the core clinical
feature of GBS. By definition, maximal weakness is
reached within 4 weeks, but most patients reach it
within 2 to 3 weeks. Thereafter, patients enter a plateau
phase that ranges from days to several weeks or months
(Fig. 1). This phase is followed by a usually much slower
and variable recovery phase. In Europe, about one-third
of GBS patients remain able to walk (“mild patients”)
[2]; about 25% of the GBS patients who are unable to
walk (“severe patients”) need artificial ventilation. This
is predominantly due to weakness of the respiratory
muscles. Despite standard treatment with intravenous
immunoglobulin (IVIG) or plasma exchange (PE) treat-
ment, about 20% of severely affected patients remain
unable to walk after 6 months. Moreover, many patients
remain otherwise disabled or severely fatigued. Even 3 to
6 years after onset, GBS has a great impact on social life
and the ability to perform activities of daily life.
Therefore, GBS remains a severe disease for which
better treatments are required.
Immunobiology
There is convincing evidence that GBS at least in some
patients is caused by an infection-induced aberrant immune
response that damages the peripheral nerves. Four key
factors were identified that control this process [1, 2, 5].
1. Anti-ganglioside antibodies
In up to 50% of patients, serum antibodies to various
gangliosides present in human peripheral nerves, including
GM1, GD1a, GalNAc-GD1a, and GQ1b, can be demon-
Features required for diagnosis
Progressive weakness in both arms and legs
Areflexia (or decreased tendon reflexes)
Features strongly supporting the diagnosis
Progression of symptoms over days to 4 weeks
Relative symmetry of symptoms
Mild sensory symptoms or signs
Cranial nerve involvement, especially bilateral weakness of facial muscles
Autonomic dysfunction
Pain (often present)
High concentration of protein in cerebrospinal fluid (CSF)
Typical electrodiagnostic features
Features that should raise doubt about the diagnosis
Severe pulmonary dysfunction with limited limb weakness at onset
Severe sensory signs with limited weakness at onset
Bladder or bowel dysfunction at onset
Fever at onset
Sharp sensory level
Slow progression with limited weakness without respiratory involvement
(consider subacute inflammatory demyelinating polyneuropathy or CIDP)
Marked persistent asymmetry of weakness
Persistent bladder or bowel dysfunction
Increased number of mononuclear cells in CSF (>50×10
6/L)
Polymorphonuclear cells in CSF
Central nervous system involvement
Table 1 Diagnosis of Guillain–
Barré Syndrome
Adapted from [4]
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plexes of different gangliosides instead of individual ones.
Interestingly, most of these antibodies are related to defined
clinical subgroups of GBS.
2. Molecular mimicry and cross-reactivity
C. jejuni isolates from GBS patients express lipooligo-
saccharides (LOS) that mimic the carbohydrates of ganglio-
sides. The type of ganglioside mimic in C. jejuni seems to
determine the specificity of the anti-ganglioside antibodies
and the associated variant of GBS. Antibodies in these
patients usually are cross-reactive; they recognize LOS as
well as gangliosides or ganglioside complexes.
GBS after Campylobacter infection in anti-GM1/GD1a/
GQ1b antibody-related cases is considered to be true
example of molecular mimicry-related disease.
3. Complement activation
Postmortem studies demonstrated that local comple-
ment activation occurs at the side of nerve damage. A
mice model for GBS showed that some anti-ganglioside
antibodies are toxic for peripheral nerves and can cause
blockade of nerve transmission and paralysis of the
nerve-muscle preparation. Additionally, there is destruc-
tion of the nerve terminal and perisynaptic Schwann
cells [6]. Antibodies to GM1 affect the sodium channels
at the nodes of Ranvier of rabbit peripheral nerves [7].
All of these effects appear to be dependent on comple-
ment activation and formation of the membrane attack
complex. The neurotoxic effects of these antibodies can
be inhibited by IVIG and the complement inhibitor
eculizumab [8].
4. Host factors
Less than 1:1,000 patients with a C. jejuni infection
will develop GBS. Host factors may influence this
susceptibility to develop GBS or the extent of nerve
damage and outcome. Single nucleotide polymorphisms
(SNPs) showed no consistent association with the suscep-
tibility to develop GBS. Evidence indicates, however, that
these SNPs may be important as disease-modifying
factors. An association has been demonstrated between
disease severity or outcome and SNPs in genes encoding
for mannose-binding lectin, FcγRIII, MMP9, and TNF-α
[2]. However, confirmation in more extensive studies is
required.
Treatment
Randomized controlled trials (RCTs) have shown that PE
and IVIG are effective in patients with GBS [9, 10]. Most
RCTs have used the GBS disability scale to determine the
effect of therapy. The GBS disability scale is a 7-point
scale, ranging from no symptoms (F=0), the ability to walk
10 m without assistance (F=2), bedbound (F=4), to death
(F=6). The first RCT on the use of IVIG in GBS was
published in 1992 and demonstrated that IVIG is as
effective as PE [11]. IVIG is applied in a regimen of 2 g/
kg bodyweight, usually as 0.4 g/kg bodyweight per day
for five consecutive days. IVIG has replaced PE as the
preferred treatment in many centers, mainly because of its
greater convenience and availability [9]. The combination
of PE followed by IVIG was not significantly better than
Fig. 1 Variations in course of disease in GBS. Indicated are the
courses of disease in mildly and severely affected GBS patients. The
effect of IVIG in GBS has only been investigated in randomized
controlled trials in patients unable to walk unaided at nadir (severely
affected patients) and not in mildly affected patients (able to walk
unaided at nadir). Whether mildly affected GBS patients may also
benefit from IVIG is yet unknown. GBS patients who initially
improve or stabilize after IVIG and subsequently deteriorate again
have a “treatment-related fluctuation” (GBS-TRF): a condition that
usually responds to an additional IVIG dose. Some GBS patients have
a severe course of disease and a slow recovery phase. The prognosis
of GBS patients can be determined using the Erasmus GBS Outcome
Scale. Whether a second IVIG dose is effective in patients with a poor
prognosis is not known yet
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surprisingly, intravenous methylprednisolone 500 mg/day
for five consecutive days alone is not beneficial in GBS
[13]. The combination of IVIG and intravenous methyl-
prednisolone was not significantly more effective than
IVIG alone. Although when a correction was made for
known prognostic factors, the combined treatment shows
some short-term effect [14]. These trials show that there is
an effect of immunotherapy on the course of GBS, but new
studies with different regimens or another therapy that is
directed toward improving the prognosis and outcome of
GBS are needed.
Prognosis of GBS
The clinical course of GBS in individual patients is highly
variable and difficult to predict. Advanced age is generally
reported to be a negative prognostic factor. Previous studies
indicate that the difference in severity of GBS can be
determined in an early phase of the disease [15]. Peroneal
nerve conduction block and age above 40 years turned out
to be independent predictors of disability at 6 months [16].
We have developed a simple clinical prognostic scoring
system that accurately predicts the chance of independent
walking after 6 months. The Erasmus GBS Outcome Scale
(EGOS) can be easily calculated after the first 2 weeks from
disease onset using age, presence of preceding diarrhea, and
GBS disability score [17]. Based on the EGOS, the
predicted chance to recover to independent walking after
6 months ranges from 1% to 83%. The accuracy of the
scale was confirmed in an independent cohort of GBS
patients. The EGOS can be used to inform individual
patients about their prognosis, additionally it can be used in
new treatment trials that more specifically target GBS
patients with poor prognosis. A slightly modified EGOS
that can calculate the prognosis only 1 week after hospital
admission is currently being constructed.
Standard-Dose IVIG is not Sufficient in some GBS Patients
There is circumstantial evidence that standard IVIG dose
(2 g/kg bodyweight) is not, or not sufficiently, effective in
some GBS patients because a proportion of GBS patients
continues to deteriorate after a standard course of IVIG
[13]. About 8% to 16% of GBS patients treated with
standard-dose IVIG deteriorate again after initial improve-
ment or stabilization. These patients have a deterioration
“treatment-related fluctuation,” in which muscle force
usually improves again after a repeated dose of IVIG
[13]. In addition, the results of a noncontrolled study in a
small series of patients suggest that a repeated dose of IVIG
may be effective in severe, unresponsive GBS patients [18].
The results of a recent pharmacokinetic study suggest that a
minor increase in serum IgG level after standard-dose IVIG
is associated with a poor outcome [19].
Pharmacokinetics of IVIG and Outcome
In a recent study by Kuitwaard et al., serum IgG levels from
174 GBS patients were determined in samples obtained
pretreatment, and at 2 weeks, 4 weeks, 3 months, and
6 months after treatment [19]. The variation in serum IgG
levels was most pronounced in the samples at 2 weeks and
to a lesser extent at 4 weeks after IVIG treatment. The IgG
level at 2 weeks showed a weak correlation with baseline
IgG level. To investigate the pharmacokinetics of IVIG, the
change in IgG was calculated by subtracting the baseline
level from the level at 2 weeks (ΔIgG). There was a large
variability in ΔIgG 2 weeks after IVIG treatment. It turned
out that patients with a low ΔIgG (lower quartiles) had a
significantly prolonged time to reach GBS disability score
≤2 (able to walk independently; log-rank P<0.001). Using
multivariate logistic regression, it was shown that baseline
IgG levels or IgG levels at 2 weeks were not significantly
associated with outcome. However, the increase in IgG
level 2 weeks after standard IVIG (ΔIgG) was associated
with outcome (P=0.027). It appeared that patients with a
ΔIgG <3.99 g/L were four times less likely (OR 0.25) and
patients with a ΔIgG of 3.99 to 7.30 g/L were three times
less likely (OR 0.26, 9) to walk unaided after 6 months than
patients with a ΔIgG >10.92 g/L. This is the first study to
show that a high increase in IgG levels after IVIG treatment
for GBS is associated with a better prognosis.
Discussion
IVIG is a proven effective treatment for GBS. Not all
patients, however, recover enough after a standard IVIG
dose. Several clinical factors are associated with the
outcome. Importantly, a low increase of serum IgG levels
after a standard IVIG dose appeared to be significantly
associated with slower recovery and a worse prognosis. The
reason why there is such a large interindividual difference
in IgG increase after IVIG treatment is not yet known. The
disease severity at the time of IVIG treatment appears to
influence the increase in serum IgG level. The lowest
increase in IgG was found in patients with more extensive
disability and weakness, as defined by the GBS disability
score and the Medical Research Council (MRC) sum score.
It is possible that more extensive immune-mediated nerve
damage results in an increase in IgG extravasation into
inflamed tissues or a higher catabolic rate. These issues
need to be studied further.
J Clin Immunol (2010) 30 (Suppl 1):S74–S78 S77IVIG is an expensive treatment that may induce
(generally minor) side effects and is currently not indicated
(proven to be effective) in mildly affected GBS patients. A
second IVIG dose potentially seems to be indicated in
patients with a poor prognosis.
Factors associated with outcome after 6 months are the
age of the patient, the presence of preceding diarrhea, and
GBS disability score or MRC sum score 1 to 2 weeks after
hospital admission; in addition, a factor to be included now
seems to be the magnitude in increase of IgG levels 2 weeks
after the start of IVIG [17, 19, 20]. Using these clinical
factors, it is possible to select a group of GBS patients with
a poor prognosis early in the course of the disease. An
international trial conducted by the Inflammatory Neurop-
athy Consortium to study the effect of a second IVIG dose
in patients with a poor prognosis based upon the EGOS is
expected to start soon.
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